Navigation Links
WellSpring Pharmaceutical Corp. Announces Hire of Wayne Miller as Vice President, Sales & Marketing, Consumer Brands

BRADENTON, Fla., Nov. 7 /PRNewswire/ -- WellSpring Pharmaceutical Corporation, a growing North American-based pharmaceutical manufacturer, today announced that Wayne Miller has been hired as the Vice President, Sales and Marketing, Consumer Brands.

Mr. Miller, an accomplished sales executive, will be responsible for designing and implementing the Company's sales and marketing strategy in the United States for its newly acquired over-the-counter product line, which includes Micatin (R) (antifungal), Emetrol (R) (anti-nausea), and Gelusil (R) (antacid). Mr. Miller will also lead the United States launch of two products that the Company currently markets in Canada, Glaxal Base(TM) and Barriere.

Mr. Miller most recently held the position of Vice President, Sales and Marketing for a North American based over-the-counter consumer health company, Origin BioMed. During his tenure with Origin BioMed, Mr. Miller was the driving force behind the successful launch of products into North America, gaining entry into several national and regional drug chains, as well as negotiating viable relationships with the North American drug wholesalers, including AmerisourceBergen, McKesson and Cardinal Health.

Along with his team at Origin BioMed, Mr. Miller was recently awarded a Nova Scotia Professional Sales Award for Innovative Sales Team. These awards honor polished professional salespeople who are changing the perception of the profession and are the driving force behind their organization's success.

"Mr. Miller is a valuable addition to our team. We are pleased to have him lead our Consumer Brands Sales and Marketing group," said Dr. Robert Vukovich, WellSpring's CEO and President. "His leadership experience, coupled with an innovative and energetic approach, makes him ideally suited to direct and guide our consumer health business."

About the Company

WellSpring Pharmaceutical Corp. has made the development, marketing and sales of new and novel prescription and OTC drug products its strategic focus. WellSpring's prescription drug products include Dyrenium (R) (diuretic) and Dibenzyline (R) (anti-hypertension) which are marketed in the US. The firm is an active acquirer of pharmaceutical brands and enhances their value through the development of product improvements and line extensions.

WellSpring is a privately held pharmaceutical company founded in 1999 by Dr. Robert A. Vukovich the firm's CEO and Chairman. Dr. Vukovich previously founded and managed Roberts Pharmaceutical Corporation of Eatontown, NJ until its acquisition by Shire Pharmaceutical Group in 1999. WellSpring owns and operates an FDA approved manufacturing plant in Oakville, Ontario, Canada. Its administrative headquarters are located in Bradenton, Florida. The firm provides contract manufacturing services to the pharmaceutical industry and manufactures prescription and OTC drug products for both the US and Canada.


Dr. Robert A. Vukovich, +1-941-552-7880, or +1-941-504-1229, or Wendy Shusko, +1-941-552-7881.

WellSpring Websites:,,

Information regarding several of the newly acquired brands can be found at the following web addresses:, and

SOURCE WellSpring Pharmaceutical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group announced that its scientific ... for isolating adipose-derived stem cells. The announcement starts a new phase toward launching the ... a component of the lipoaspirate obtained from liposuction of excess adipose tissue. , ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care hub ... northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. , ... cell medicine to patients from around the world. , The clinics will be headed by ...
(Date:11/30/2015)... MONTREAL , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... that it has joined the American Business Act on Climate ... economy that are standing with the Obama Administration to demonstrate ... for a strong outcome to the COP21 Paris ... . --> Sarnia, Canada . ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, ... assistant chemistry professor Jan Halámek, is taking crime ...   --> ...   --> --> ... UAlbany have discovered a straightforward concept for identifying ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
Breaking Biology News(10 mins):